simendan has been researched along with charybdotoxin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katsube, Y; Sperelakis, N; Sunagawa, M; Yokoshiki, H | 1 |
| Akar, F; Katircioglu, SF; Manavbasi, Y; Parlar, AI; Ulus, AT | 1 |
2 other study(ies) available for simendan and charybdotoxin
| Article | Year |
|---|---|
Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Charybdotoxin; Enzyme Inhibitors; Female; Glyburide; Hydrazones; Hypoglycemic Agents; Male; Membrane Potentials; Mesenteric Arteries; Patch-Clamp Techniques; Potassium Channels; Pyridazines; Rats; Simendan; Vasodilator Agents | 1997 |
The gender differences in the relaxation to levosimendan of human internal mammary artery.
Topics: 4-Aminopyridine; Anti-Arrhythmia Agents; Charybdotoxin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Glyburide; Humans; Hydrazones; Male; Mammary Arteries; Middle Aged; Potassium Channel Blockers; Pyridazines; Sex Characteristics; Simendan; Vasodilation | 2007 |